Details of the Drug

General Information of Drug (ID: DMG7XHE)

Drug Name
Monalizumab
Synonyms IPH2201
Indication
Disease Entry ICD 11 Status REF
Chronic lymphocytic leukaemia 2A82.0 Phase 1/2 [1]
Head and neck cancer 2D42 Phase 1/2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
Drug Type
Antibody
Cross-matching ID
UNII
3ZXZ2V0588
DrugBank ID
DB12824
TTD ID
D0RI6Q
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
NKG2-A/B-activating NK receptor (NKG2A) TTC4IMS NKG2A_HUMAN Antagonist [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02643550) Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)